drugset
drugset / Trial / NCT01232439

A Study of Brain Receptor Occupancy in Healthy Subjects

NCT01232439 ↗

Phase 1 Completed 13 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.

Timeline

Start
2010-12
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aticaprant Small molecule 2 mg Oral

Indications

alcohol dependence